Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
By D. V. Von Hoff, R. Ramanathan, M. Borad, D. Laheru, Lon S. Smith, T. Wood, R. Korn, N. Desai, V. Trieu, J. Iglesias and 6 more. Journal of Clinical Oncology, 2011
1,030 citations recorded by the source corpus.
Subfields: Biotechnology, Oncology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/539d82bce4ad3b1bb2fec7b377b87657c2f64123
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
- M. V. Vander Heiden
- D. Tuveson
- A. Klein
- D. Bar-Sagi
- Craig B. Thompson
- G. Miller
- D. Öhlund
- Ela Elyada
In Rheumatology
Citations in the corpus
- Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors (2017, background): “133 Iron oxide nanoparticles (IONPs) were also prepared for expressing a uPAR-targeted moiety on their surface.”
- Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma (2012, methodology): “One regimen combined gemcitabine with nab-paclitaxel, an albumin-coated formulation of taxol with an extended half-life of >10 hr in the circulation (Von Hoff et al., 2011).”
- Recent progress in pancreatic cancer (2013, methodology): “For example, the albumin in nab-paclitaxel (albumin-bound paclitaxel) may bind to SPARC, a protein expressed at high levels in the desmoplastic stroma, increasing the delivery of paclitaxel to the neoplastic cells.(58,59) Cell-matrix interactions could also be targeted therapeutically, and some inve”
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015, neutral): “KPS 90-100 n = 241 n = 241 KPS 70-80 n = 164† n = 146 Neutropenia All treated 297 (73) 43 (11) 101 (25) 107 (26) 46 (11) 225 (58) 35 (9) 86 (22) 83 (21) 21 (5) KPS 90-100 185 (77) 22 (9) 65 (27) 67 (28) 31 (13) 156 (65) 20 (8) 60 (25) 60 (25) 16 (7) KPS 70-80 112 (68) 21 (13) 36 (22) 40 (24) 15 (9) ”
- Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. (2015, positive): “In light of this, the recent clinical success of a protein–drug conjugate albumin–paclitaxel (nab-paclitaxel, Abraxane) in PDAC is particularly tantalizing (34), and warrants further investigation into metabolic scavenging and how it can be exploited therapeutically.”
- Fibroblast heterogeneity in the cancer wound (2014, background): “By expressing members of the matrix metalloproteinase (MMP) family, CAFs can facilitate tumor growth, invasion, and metastasis (Poulsom et al., 1992; Stetler-Stevenson et al., 1993; Sternlicht et al., 1999; Vosseler et al., 2009; Zigrino et al., 2009).”